



ERIC HOLCOMB, GOVERNOR
STATE OF INDIANA

Office of Medicaid Policy and Planning
MS 07, 402 W. WASHINGTON STREET, ROOM W382
INDIANAPOLIS, IN 46204-2739

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee

May 6, 2022

11 A.M. EDT

Virtual Meeting – Microsoft Teams Link Provided Below

1. Call to Order-Chair
2. Preferred Drug List: Therapeutic Class Re-Review – Discussion and Recommendations
3. Preferred Drug List: Therapeutic Class Re-Review
 - a) CNS and Others
 - i. Agents for the Treatment of Opiate Addiction
 - ii. Antiemetic/Antivertigo Agents
 - iii. Antiseizure Agents
 - iv. Gastroprotective NSAIDs
 - v. Movement Disorder Agents
 - vi. Narcotic Antitussive/1st Generation Antihistamine Combinations
 - vii. Narcotics
 - viii. Skeletal Muscle Relaxants
 - ix. Smoking Deterrent Agents
 - b) Dermatologic Agents
 - i. Acne Agents
 - ii. Antipsoriatic Agents



c) Endocrine

- i. Anaphylaxis Agents
- ii. Bone Formation Stimulating Agents
- iii. Bone Resorption Inhibitors
- iv. DPP4 Inhibitors and Combination Agents
- v. GLP-1 Receptor Agonists and Combinations
- vi. Glucagon Agents
- vii. Growth Hormones
- viii. Injectable Hypoglycemics, Insulin
- ix. Miscellaneous Oral Antidiabetic Agents
- x. SGLT2 Inhibitors and Combinations
- xi. Testosterones

d) Estrogen and Related Agents

- i. Estrogen and Related Agents

e) Gastrointestinal Agents

- i. Anti-ulcer Agents
- ii. *H. Pylori* Agents
- iii. H2 Receptor Antagonists
- iv. Laxatives and Cathartics
- v. Pancreatic Enzymes
- vi. Proton Pump Inhibitors
- vii. Ulcerative Colitis Agents

f) Genitourinary Agents

- i. Benign Prostatic Hypertrophy Agents
- ii. Urinary Tract Antispasmodic/Anti-Incontinence Agents

g) Hematologic Agents

- i. Direct Factor Xa Inhibitors
- ii. Direct Thrombin Inhibitors
- iii. Hematinics

- iv. Heparin and Related Products
 - v. Leukocyte (WBC) Stimulants
 - vi. Platelet Aggregation Inhibitors
- h) Targeted Immunomodulators
 - i) Topical Agents
 - i. Miotics-Intraocular Pressure Reducers
 - ii. Ophthalmic Antihistamines
 - iii. Ophthalmic Anti-Inflammatory Agents
 - iv. Ophthalmic Mast Cell Stabilizers
 - v. Otic Preparations
 - vi. Treatments of Xerophthalmia (dry eye)
 - vii. Topical Anti-Inflammatory Agents-NSAIDs
 - viii. Topical Antiparasitics
 - ix. Topical Immunomodulators
 - x. Topical Postherpetic Neuralgia Agents
- 4. Public Comment
 - 5. Other Business
 - 6. Adjourn

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

https://teams.microsoft.com/l/meetup-join/19%3ameeting_MzYzMmUwNTktOTIIZi00OWY0LThhMDctNWZkMjAwYzNIZWU2%40thread.v2/0?context=%7b%22Tid%22%3a%22db05faca-c82a-4b9d-b9c5-0f64b6755421%22%2c%22Oid%22%3a%2253df74d0-e68c-46fe-81f5-fac4b0bd8ef8%22%7d

Join with a video conferencing device

425899727@t.plcm.vc

Video Conference ID: 119 888 828 9

[Alternate VTC instructions](#)

Or call in (audio only)

[+1 952-222-7450,,282344689#](#) United States, Bloomington

Phone Conference ID: 282 344 689#